Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment Sponsor: Aura Biosciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment Sponsor: Aura Biosciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment Sponsor: Aura Biosciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
